Gilead Sciences (GILD) Capital Expenditures (2009 - 2026)

Gilead Sciences has reported Capital Expenditures for 18 years, with the latest figure at $117.0 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 12.5% year-over-year to $117.0 million; the trailing twelve-month figure through Mar 2026 stood at $576.0 million (up 10.34% YoY), and the FY2025 full-year result was $563.0 million, up 7.65% from the prior year.
• Capital Expenditures for Q1 2026 stood at $117.0 million, down from $205.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $247.0 million in Q1 2022, with the low at $104.0 million in Q1 2025.
• Historically, Capital Expenditures has averaged $148.0 million across 5 years, with a median of $141.0 million in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 49.7% — and 2023, when it tumbled 55.87%.
• Gilead Sciences' Capital Expenditures stood at $181.0 million in 2022, then increased by 18.78% to $215.0 million in 2023, then tumbled by 31.63% to $147.0 million in 2024, then soared by 39.46% to $205.0 million in 2025, then tumbled by 42.93% to $117.0 million in 2026.
• The last three Capital Expenditures figures came in at $117.0 million (Q1 2026), $205.0 million (Q4 2025), and $147.0 million (Q3 2025), per Business Quant data.